Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicentre Trial to Evaluate the Time Associated With the Preparation and Administration of Denosumab and Pamidronate in Subjects With Solid Tumors and Metastatic Bone Disease in Canada

Trial Profile

An Open-Label, Multicentre Trial to Evaluate the Time Associated With the Preparation and Administration of Denosumab and Pamidronate in Subjects With Solid Tumors and Metastatic Bone Disease in Canada

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 26 Feb 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary) ; Pamidronic acid
  • Indications Bone cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 17 Feb 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, according to ClinicalTrials.gov record.
    • 09 Jun 2014 Planned initiation date changed from 1 May 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
    • 12 May 2014 Planned initiation date changed from 1 Apr 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top